Regulation of MAPKs by growth factors and receptor tyrosine kinases

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1773, Issue 8, 2007, Pages 1161-1176

  Katz, Menachem ^a   Amit, Ido ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer; Growth factor; Signal transduction; Transcription; Tyrosine kinase

Indexed keywords

GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE;

CELL FATE; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBSTRATE; GENE EXPRESSION REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; ENDOCYTOSIS; FEEDBACK; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; ONCOGENES; PHOSPHORYLATION; RECEPTOR CROSS-TALK; RECEPTOR PROTEIN-TYROSINE KINASES; RNA-BINDING PROTEINS;

EID: 34547226194     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.01.002     Document Type: Review

References (194)

1. Yarden Y., and Ullrich A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57 (1988) 443-478
2. Blume-Jensen P., and Hunter T. Oncogenic kinase signaling. Nature 411 (2001) 355-365
3. Heldin C.-H., and Ostman A. Ligand-induced dimerization of growth factor receptors: variations on the theme. Cytok. Growth Factor Rev. 7 (1996) 33-40
4. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116 (2004) 191-203
5. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., and Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110 (2002) 775-787
6. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., and Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110 (2002) 763-773
7. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149
8. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
9. Hubbard S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev., Mol. Cell Biol. 5 (2004) 464-471
10. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 70 (2001) 281-312
11. Noh D.Y., Shin S.H., and Rhee S.G. Phosphoinositide-specific phospholipase C and mitogenic signaling. Biochim. Biophys. Acta. 1242 (1995) 99-113
12. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., Waterfield M.D., and Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370 (1994) 527-532
13. Meier R., and Hemmings B.A. Regulation of protein kinase B. J. Recept. Signal Transduction Res. 19 (1999) 121-128
14. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat. Rev., Mol. Cell Biol. 3 (2002) 651-662
15. Kyriakis J.M., App H., Zhang X.F., Banerjee P., Brautigan D.L., Rapp U.R., and Avruch J. Raf-1 activates MAP kinase-kinase. Nature 358 (1992) 417-421
16. Yoon S., and Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24 (2006) 21-44
17. Murphy L.O., and Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem. Sci. 31 (2006) 268-275
18. Kato Y., Tapping R.I., Huang S., Watson M.H., Ulevitch R.J., and Lee J.D. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395 (1998) 713-716
19. Chao T.H., Hayashi M., Tapping R.I., Kato Y., and Lee J.D. MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. J. Biol. Chem. 274 (1999) 36035-36038
20. Abe J., Kusuhara M., Ulevitch R.J., Berk B.C., and Lee J.D. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J. Biol. Chem. 271 (1996) 16586-16590
21. Kamakura S., Moriguchi T., and Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 274 (1999) 26563-26571
22. English J.M., Vanderbilt C.A., Xu S., Marcus S., and Cobb M.H. Isolation of MEK5 and differential expression of alternatively spliced forms. J. Biol. Chem. 270 (1995) 28897-28902
23. Sun W., Wei X., Kesavan K., Garrington T.P., Fan R., Mei J., Anderson S.M., Gelf E.W., and Johnson G.L. MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Mol. Cell. Biol. 23 (2003) 2298-2308
24. Xu B.E., Stippec S., Lenertz L., Lee B.H., Zhang W., Lee Y.K., and Cobb M.H. WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. J. Biol. Chem. 279 (2004) 7826-7831
25. Pearson G.W., Earnest S., and Cobb M.H. Cyclic AMP selectively uncouples mitogen-activated protein kinase cascades from activating signals. Mol. Cell. Biol. 26 (2006) 3039-3047
26. Kato Y., Chao T.H., Hayashi M., Tapping R.I., and Lee J.D. Role of BMK1 in regulation of growth factor-induced cellular responses. Immunol. Res. 21 (2000) 233-237
27. Hayashi M., Tapping R.I., Chao T.H., Lo J.F., King C.C., Yang Y., and Lee J.D. BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J. Biol. Chem. 276 (2001) 8631-8634
28. Watson F.L., Heerssen H.M., Bhattacharyya A., Klesse L., Lin M.Z., and Segal R.A. Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat. Neurosci. 4 (2001) 981-988
29. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
30. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
31. Teramoto H., Coso O.A., Miyata H., Igishi T., Miki T., and Gutkind J.S. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J. Biol. Chem. 271 (1996) 27225-27228
32. Minden A., Lin A., Claret F.X., Abo A., and Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81 (1995) 1147-1157
33. Fanger G.R., Johnson N.L., and Johnson G.L. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J. 16 (1997) 4961-4972
34. Lambert J.M., Lambert Q.T., Reuther G.W., Malliri A., Siderovski D.P., Sondek J., Collard J.G., and Der C.J. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat. Cell Biol. 4 (2002) 621-625
35. Han J., Luby-Phelps K., Das B., Shu X., Xia Y., Mosteller R.D., Krishna U.M., Falck J.R., White M.A., and Broek D. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279 (1998) 558-560
36. Logan S.K., Falasca M., Hu P., and Schlessinger J. Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway. Mol. Cell. Biol. 17 (1997) 5784-5790
37. Hashimoto A., Kurosaki M., Gotoh N., Shibuya M., and Kurosaki T. Shc regulates epidermal growth factor-induced activation of the JNK signaling pathway. J. Biol. Chem. 274 (1999) 20139-20143
38. Becker E., Huynh-Do U., Holland S., Pawson T., Daniel T.O., and Skolnik E.Y. Nck-interacting Ste20 kinase couples Eph receptors to c-Jun N-terminal kinase and integrin activation. Mol. Cell. Biol. 20 (2000) 1537-1545
39. Su Y.C., Han J., Xu S., Cobb M., and Skolnik E.Y. NIK is a new Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain. EMBO J. 16 (1997) 1279-1290
40. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
41. Zwang Y., and Yarden Y. p38 MAP kinase mediates stress_induced internalization of EGFR: implications for cancer chemotherapy. EMBO J 25 (2006) 4195-4206
42. Vergarajauregui S., San Miguel A., and Puertollano R. Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. Traffic 7 (2006) 686-698
43. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80 (1995) 179-185
44. Traverse S., Seedorf K., Paterson H., Marshall C.J., Cohen P., and Ullrich A. EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr. Biol. 4 (1994) 694-701
45. Dikic I., Schlessinger J., and Lax I. PC12 cells overexpressing the insulin receptor undergo insulin-dependent neuronal differentiation. Curr. Biol. 4 (1994) 702-708
46. Woods D., Parry D., Cherwinski H., Bosch E., Lees E., and McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17 (1997) 5598-5611
47. Wellbrock C., Karasarides M., and Marais R. The RAF proteins take centre stage. Nat. Rev., Mol. Cell Biol. 5 (2004) 875-885
48. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
49. Garnett M.J., Rana S., Paterson H., Barford D., and Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20 (2005) 963-969
50. York R.D., Yao H., Dillon T., Ellig C.L., Eckert S.P., McCleskey E.W., and Stork P.J. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392 (1998) 622-626
51. Chadee D.N., and Kyriakis J.M. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat. Cell Biol. 6 (2004) 770-776
52. Kolch W., Heidecker G., Kochs G., Hummel R., Vahidi H., Mischak H., Finkenzeller G., Marme D., and Rapp U.R. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364 (1993) 249-252
53. Marais R., Light Y., Mason C., Paterson H., Olson M.F., and Marshall C.J. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 280 (1998) 109-112
54. King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., and Marshall M.S. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396 (1998) 180-183
55. Chaudhary A., King W.G., Mattaliano M.D., Frost J.A., Diaz B., Morrison D.K., Cobb M.H., Marshall M.S., and Brugge J.S. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr. Biol. 10 (2000) 551-554
56. Corbit K.C., Foster D.A., and Rosner M.R. Protein kinase Cdelta mediates neurogenic but not mitogenic activation of mitogen-activated protein kinase in neuronal cells. Mol. Cell. Biol. 19 (1999) 4209-4818
57. Corbit K.C., Soh J.W., Yoshida K., Eves E.M., Weinstein I.B., and Rosner M.R. Different protein kinase C isoforms determine growth factor specificity in neuronal cells. Mol. Cell. Biol. 20 (2000) 5392-5403
58. Wang Q., Zhou Y., Wang X., and Evers B.M. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 25 (2006) 43-50
59. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., Vande Woude G.F., and Ahn N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265 (1994) 966-970
60. Sharp L.L., Schwarz D.A., Bott C.M., Marshall C.J., and Hedrick S.M. The influence of the MAPK pathway on T cell lineage commitment. Immunity 7 (1997) 609-618
61. Whalen A.M., Galasinski S.C., Shapiro P.S., Nahreini T.S., and Ahn N.G. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol. Cell. Biol. 17 (1997) 1947-1958
62. Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A., and Kaplan D.R. Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. Neuron 12 (1994) 691-705
63. Obermeier A., Bradshaw R.A., Seedorf K., Choidas A., Schlessinger J., and Ullrich A. Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLC gamma. EMBO J. 13 (1994) 1585-1590
64. Buday L., and Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73 (1993) 611-620
65. Khokhlatchev A.V., Canagarajah B., Wilsbacher J., Robinson M., Atkinson M., Goldsmith E., and Cobb M.H. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93 (1998) 605-615
66. Whitehurst A., Cobb M.H., and White M.A. Stimulus-coupled spatial restriction of extracellular signal-regulated kinase 1/2 activity contributes to the specificity of signal-response pathways. Mol. Cell. Biol. 24 (2004) 10145-10150
67. Torii S., Kusakabe M., Yamamoto T., Maekawa M., and Nishida E. Sef is a spatial regulator for Ras/MAP kinase signaling. Dev. Cell 7 (2004) 33-41
68. Roy M., Li Z., and Sacks D.B. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling. Mol. Cell. Biol. 25 (2005) 7940-7952
69. Ishibe S., Joly D., Liu Z.X., and Cantley L.G. Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol. Cell 16 (2004) 257-267
70. Wiley H.S. Trafficking of the ErbB receptors and its influence on signaling. Exp. Cell Res. 284 (2003) 78-88
71. Thien C.B., and Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev., Mol. Cell Biol. 2 (2001) 294-307
72. Marmor M.D., and Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23 (2004) 2057-2070
73. Di Guglielmo G.M., Baass P.C., Ou W.J., Posner B.I., and Bergeron J.J. Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. EMBO J. 13 (1994) 4269-4277
74. Jiang X., and Sorkin A. Coordinated traffic of Grb2 and Ras during epidermal growth factor receptor endocytosis visualized in living cells. Mol. Biol. Cell 3 (2002) 522-535
75. Kranenburg O., Verlaan I., and Moolenaar W.H. Dynamin is required for the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase. J. Biol. Chem. 274 (1999) 35301-35304
76. Pennock S., and Wang Z. Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. Mol. Cell. Biol. 23 (2003) 5803-5815
77. Vieira A.V., Lamaze C., and Schmid S.L. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274 (1996) 2086-2088
78. Burke P., Schooler K., and Wiley H.S. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell 12 (2001) 1897-1910
79. Mochizuki N., Yamashita S., Kurokawa K., Ohba Y., Nagai T., Miyawaki A., and Matsuda M. Spatio-temporal images of growth-factor-induced activation of Ras and Rap1. Nature 411 (2001) 1065-1068
80. Teis D., Wunderlich W., and Huber L.A. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev. Cell 3 (2002) 803-814
81. Rotblat B., Yizhar O., Haklai R., Ashery U., and Kloog Y. Ras and its signals diffuse through the cell on randomly moving nanoparticles. Cancer Res. 66 (2006) 1974-1981
82. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev., Mol. Cell Biol. 7 (2006) 505-516
83. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev., Mol. Cell Biol. 2 (2001) 127-137
84. Dikic I., and Giordano S. Negative receptor signalling. Curr. Opin. Cell Biol. 15 (2003) 128-135
85. Freeman M. Feedback control of intercellular signalling in development. Nature 408 (2000) 313-319
86. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M., and Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401 (1999) 173-177
87. Fiorini M., Ballaro C., Sala G., Falcone G., Alema S., and Segatto O. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 21 (2002) 6530-6539
88. Smolen P., Baxter D.A., and Byrne J.H. Modeling transcriptional control in gene networks-Methods, recent results, and future directions. Bull. Math. Biol. 62 (2000) 247-292
89. Kitano H. Biological robustness. Nat. Rev., Genet. 5 (2004) 826-837
90. Lau L.F., and Nathans D. Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 1182-1186
91. Greenberg M.E., Hermanowski A.L., and Ziff E.B. Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription. Mol. Cell. Biol. 6 (1986) 1050-1057
92. Farooq A., and Zhou M.M. Structure and regulation of MAPK phosphatases. Cell. Signal. 16 (2004) 769-779
93. Brummer T., Naegele H., Reth M., and Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 22 (2003) 8823-8834
94. Treisman R. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8 (1996) 205-215
95. Lai Z.C., and Rubin G.M. Negative control of photoreceptor development in Drosophila by the product of the yan gene, an ETS domain protein. Cell 70 (1992) 609-620
96. Yates P.R., Atherton G.T., Deed R.W., Norton J.D., and Sharrocks A.D. Id helix-loop-helix proteins inhibit nucleoprotein complex formation by the TCF ETS-domain transcription factors. EMBO J. 18 (1999) 968-976
97. Molina C.A., Foulkes N.S., Lalli E., and Sassone-Corsi P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75 (1993) 875-886
98. Svaren J., Sevetson B.R., Apel E.D., Zimonjic D.B., Popescu N.C., and Milbrandt J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol. Cell. Biol. 16 (1996) 3545-3553
99. Yoshioka K., Deng T., Cavigelli M., and Karin M. Antitumor promotion by phenolic antioxidants: inhibition of AP-1 activity through induction of Fra expression. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4972-4976
100. Kitabayashi I., Chiu R., Gachelin G., and Yokoyama K. E1A dependent up-regulation of c-jun/AP-1 activity. Nucleic Acids Res. 19 (1991) 649-655
101. Bakheet T., Williams B.R., and Khabar K.S. ARED 3.0: the large and diverse AU-rich transcriptome. Nucleic Acids Res. 34 (2006) D111-D114
102. Barreau C., Paillard L., and Osborne H.B. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res. 33 (2005) 7138-7150
103. Carballo E., Lai W.S., and Blackshear P.J. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281 (1998) 1001-1005
104. Wilson T., and Treisman R. Removal of poly(A) and consequent degradation of c-fos mRNA facilitated by 3′ AU-rich sequences. Nature 336 (1988) 396-399
105. Meijlink F., Curran T., Miller A.D., and Verma I.M. Removal of a 67-base-pair sequence in the noncoding region of protooncogene fos converts it to a transforming gene. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4987-4991
106. Jing Q., Huang S., Guth S., Zarubin T., Motoyama A., Chen J., Di Padova F., Lin S.C., Gram H., and Han J. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120 (2005) 623-634
107. Li X., and Carthew R.W. A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the Drosophila eye. Cell 123 (2005) 1267-1277
108. Ferrell J.E., and Xiong W. Bistability in cell signaling: how to make continuous processes discontinuous, and reversible processes irreversible. Chaos 11 (2001) 227-236
109. Jones S.M., and Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat. Cell Biol. 3 (2001) 165-172
110. Xiong W., and Ferrell Jr. J.E. A positive-feedback-based bistable 'memory module' that governs a cell fate decision. Nature 426 (2003) 460-465
111. Murphy L.O., Smith S., Chen R.H., Fingar D.C., and Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4 (2002) 556-564
112. Seger R., Seger D., Reszka A.A., Munar E.S., Eldar-Finkelman H., Dobrowolska G., Jensen A.M., Campbell J.S., Fischer E.H., and Krebs E.G. Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. J. Biol. Chem. 269 (1994) 25699-25709
113. Pages G., Lenormand P., L'Allemain G., Chambard J.C., Meloche S., and Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8319-8323
114. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 (1994) 841-852
115. Graves L.M., Guy H.I., Kozlowski P., Huang M., Lazarowski E., Pope R.M., Collins M.A., Dahlstrand E.N., Earp III H.S., and Evans D.R. Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature 403 (2000) 328-332
116. Palmer A., Gavin A.C., and Nebreda A.R. A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1. EMBO J. 17 (1998) 5037-5047
117. Kawada M., Yamagoe S., Murakami Y., Suzuki K., Mizuno S., and Uehara Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15 (1997) 629-637
118. Lavoie J.N., L'Allemain G., Brunet A., Muller R., and Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271 (1996) 20608-20616
119. Treinies I., Paterson H.F., Hooper S., Wilson R., and Marshall C.J. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol. Cell. Biol. 19 (1999) 321-329
120. Wright J.H., Munar E., Jameson D.R., Andreassen P.R., Margolis R.L., Seger R., and Krebs E.G. Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11335-11340
121. Zecevic M., Catling A.D., Eblen S.T., Renzi L., Hittle J.C., Yen T.J., Gorbsky G.J., and Weber M.J. Active MAP kinase in mitosis: localization at kinetochores and association with the motor protein CENP-E. J. Cell Biol. 142 (1998) 1547-1558
122. Shapiro P.S., Vaisberg E., Hunt A.J., Tolwinski N.S., Whalen A.M., McIntosh J.R., and Ahn N.G. Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen. J. Cell Biol. 142 (1998) 1533-1545
123. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., and Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12 (1998) 3008-3019
124. Rahmouni S., Cerignoli F., Alonso A., Tsutji T., Henkens R., Zhu C., Louis-dit-Sully C., Moutschen M., Jiang W., and Mustelin T. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat. Cell Biol. 8 (2006) 524-531
125. Eves E.M., Shapiro P., Naik K., Klein U.R., Trakul N., and Rosner M.R. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol. Cell 23 (2006) 561-574
126. Zhu J., Woods D., McMahon M., and Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12 (1998) 2997-3007
127. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., and Horwitz A.R. Cell migration: integrating signals from front to back. Science 302 (2003) 1704-1709
128. Lauffenburger D.A., and Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 84 (1996) 359-369
129. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev., Mol. Cell Biol. 5 (2004) 816-826
130. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev., Mol. Cell Biol. 4 (2003) 915-925
131. Wells A., Kassis J., Solava J., Turner T., and Lauffenburger D.A. Growth factor-induced cell motility in tumor invasion. Acta Oncol. 41 (2002) 124-130
132. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., and Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376 (1995) 768-771
133. Ebens A., Brose K., Leonardo E.D., Hanson Jr. M.G., Bladt F., Birchmeier C., Barres B.A., and Tessier-Lavigne M. Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron 17 (1996) 1157-1172
134. Fitzgerald J.S., Busch S., Wengenmayer T., Foerster K., de la Motte T., Poehlmann T.G., and Markert U.R. Signal transduction in trophoblast invasion. Chem. Immunol. Allergy 88 (2005) 181-199
135. Xian C.J., and Zhou X.F. EGF family of growth factors: essential roles and functional redundancy in the nerve system. Front. Biosci. 9 (2004) 85-92
136. Miettinen P.J., Huotari M., Koivisto T., Ustinov J., Palgi J., Rasilainen S., Lehtonen E., Keski-Oja J., and Otonkoski T. Impaired migration and delayed differentiation of pancreatic islet cells in mice lacking EGF-receptors. Development 127 (2000) 2617-2627
137. Mine N., Iwamoto R., and Mekada E. HB-EGF promotes epithelial cell migration in eyelid development. Development 132 (2005) 4317-4326
138. Hudson L.G., and McCawley L.J. Contributions of the epidermal growth factor receptor to keratinocyte motility. Microsc. Res. Tech. 43 (1998) 444-455
139. Kassis J., Lauffenburger D.A., Turner T., and Wells A. Tumor invasion as dysregulated cell motility. Semin. Cancer Biol. 11 (2001) 105-117
140. Chen P., Xie H., Sekar M.C., Gupta K., and Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J. Cell Biol. 127 (1994) 847-857
141. Chen P., Murphy-Ullrich J.E., and Wells A. A role for gelsolin in actuating epidermal growth factor receptor-mediated cell motility. J. Cell Biol. 134 (1996) 689-698
142. Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., and Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70 (1992) 401-410
143. Webb C.P., Van Aelst L., Wigler M.H., and Woude G.F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8773-8778
144. Giroux S., Tremblay M., Bernard D., Cardin-Girard J.F., Aubry S., Larouche L., Rousseau S., Huot J., Landry J., Jeannotte L., and Charron J. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9 (1999) 369-372
145. Verbeek B.S., Adriaansen-Slot S.S., Vroom T.M., Beckers T., and Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 425 (1998) 145-150
146. Irie H.Y., Pearline R.V., Grueneberg D., Hsia M., Ravichandran P., Kothari N., Natesan S., and Brugge J.S. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 171 (2005) 1023-1034
147. Glading A., Chang P., Lauffenburger D.A., and Wells A. Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J. Biol. Chem. 275 (2000) 2390-2398
148. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P., and Cheresh D.A. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 137 (1997) 481-492
149. Totsukawa G., Wu Y., Sasaki Y., Hartshorne D.J., Yamakita Y., Yamashiro S., and Matsumura F. Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts. J. Cell Biol. 164 (2004) 427-439
150. Potempa S., and Ridley A.J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 9 (1998) 2185-2200
151. Kermorgant S., Zicha D., and Parker P.J. PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J. 23 (2004) 3721-3734
152. Carragher N.O., Westhoff M.A., Fincham V.J., Schaller M.D., and Frame M.C. A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src. Curr. Biol. 13 (2003) 1442-1450
153. Malliri A., Symons M., Hennigan R.F., Hurlstone A.F., Lamb R.F., Wheeler T., and Ozanne B.W. The transcription factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. J. Cell Biol. 143 (1998) 1087-1099
154. Gordon S.R., and Staley C.A. Role of the cytoskeleton during injury-induced cell migration in corneal endothelium. Cell Motil. Cytoskelet. 16 (1990) 47-57
155. Bauer J., Margolis M., Schreiner C., Edgell C.J., Azizkhan J., Lazarowski E., and Juliano R.L. In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins. J. Cell. Physiol. 153 (1992) 437-449
156. Reddy K.B., Nabha S.M., and Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22 (2003) 395-403
157. Vial E., Sahai E., and Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4 (2003) 67-79
158. Pullikuth A., McKinnon E., Schaeffer H.J., and Catling A.D. The MEK1 scaffolding protein MP1 regulates cell spreading by integrating PAK1 and Rho signals. Mol. Cell. Biol. 25 (2005) 5119-5133
159. Barros J.C., and Marshall C.J. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J. Cell. Sci. 118 (2005) 1663-1671
160. Huang C., Rajfur Z., Borchers C., Schaller M.D., and Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature 424 (2003) 219-223
161. Hauck C.R., Sieg D.J., Hsia D.A., Loftus J.C., Gaarde W.A., Monia B.P., and Schlaepfer D.D. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res. 61 (2001) 7079-7090
162. Yujiri T., Ware M., Widmann C., Oyer R., Russell D., Chan E., Zaitsu Y., Clarke P., Tyler K., Oka Y., Fanger G.R., Henson P., and Johnson G.L. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7272-7277
163. Xia Y., Makris C., Su B., Li E., Yang J., Nemerow G.R., and Karin M. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5243-5248
164. Huang C., Jacobson K., and Schaller M.D. MAP kinases and cell migration. J. Cell. Sci. 17 (2004) 4619-4628
165. Cui X., Kim H.J., Kuiatse I., Kim H., Brown P.H., and Lee A.V. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res. 66 (2006) 5304-5313
166. Zohn I.E., Li Y., Skolnik E.Y., Anderson K.V., Han J., and Niswander L. p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell 125 (2006) 957-969
167. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., McCormick F., and Rauen K.A. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311 (2006) 1287-1290
168. Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., Hennekam R.C., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., and Matsubara Y. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 38 (2006) 294-296
169. Lev S., Blechman J.M., Givol D., and Yarden Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit. Rev. Oncog. 5 (1994) 141-168
170. Ashman L.K. The biology of stem cell factor and its receptor C-kit. Int. J. Biochem. Cell Biol. 31 (1999) 1037-1051
171. Chen H.E., Chang S., Trub T., and Neel B.G. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 16 (1996) 3685-3697
172. Jhiang S.M. The Ret proto-oncogene in human cancer. Oncogene 19 (2000) 5590-5597
173. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
174. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
175. Tracy S., Mukohara T., Hansen M., Meyerson M., Johnson B.E., and Janne P.A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64 (2004) 7241-7244
176. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther. 102 (2004) 37-46
177. Maurizi M., Almadori G., Ferrandina G., Distefano M., Romanini M.E., Cadoni G., Benedetti-Panici P., Paludetti G., Scambia G., and Mancuso S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer 74 (1996) 1253-1257
178. Liang K., Ang K.K., Milas L., Hunter N., and Fan Z. The epidermal growth factor receptor mediates radioresistance. Int. J. Radiat. Oncol., Biol., Phys. 57 (2003) 246-254
179. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., and Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 (1985) 144-147
180. Ekstrand A.J., Sugawa N., James C.D., and Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4309-4313
181. Yamazaki H., Fukui Y., Ueyama Y., Tamaoki N., Kawamoto T., Taniguchi S., and Shibuya M. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol. Cell. Biol. 8 (1988) 1816-1820
182. H.S. Huang, M. Nagane, C.K. Klingbeil, H. Lin, R. Nishikawa, X.D. Ji, C.M. Huang, G.N. Gill, H.S. Wiley and W.K. Cavenee, The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling, J. Biol. Chem. 272 (1997) 2927-35 0021-9258.
183. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., and Wong A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55 (1995) 5536-5539
184. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., Reist C.J., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55 (1995) 3140-3148
185. Hynes N.E., and Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta 1198 (1994) 165-184
186. Klapper L.N., Kirschbaum M.H., Sela M., and Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77 (2000) 25-79
187. Hirai T., Kuwahara M., Yoshida K., Kagawa Y., Hihara J., Yamashita Y., and Toge T. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis. Esophagus 11 (1998) 221-225
188. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., and Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 12 (1990) 1183-1188
189. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl. 4 (2001) S9-S15
190. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev., Cancer 3 (2003) 11-22
191. Papin C., Denouel-Galy A., Laugier D., Calothy G., and Eychene A. Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J. Biol. Chem. 273 (1998) 24939-24947
192. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
193. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
194. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., and Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362